Recently, the FDA approved melphalan for liver-directed treatment of uveal melanoma. In this interview, Oncology Data Advisor Editorial Board member Dr. Richard Carvajal, Deputy Physician-in-Chief and Director of Medical Oncology at Northwell Health Cancer Institute in New York, discusses the approval and the trial that led to it, as well as share exciting insights on the potential future landscape of this rare disease.   Oncology Data Advisor: Welcome to Oncology Data Advisor, a digital re...

The FDA has approved melphalan for injection (Hepzato Kit™/Hepatic Delivery System), containing melphalan (Hepzato™, Delcath Systems, Inc.) as a liver-directed treatment for patients with uveal melanoma with unresectable hepatic metastases affecting ≤50% of the liver. This treatment is permitted for those with no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. This application was granted or...